Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Merck
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket   Start Trial Date Filed 2017-06-30
Court District Court, N.D. West Virginia Date Terminated
Cause 35:271 Patent Infringement Assigned To Irene Patricia Murphy Keeley
Jury Demand None Referred To
Parties BIOGEN INTERNATIONAL GMBH; BIOGEN MA, INC.; MYLAN PHARMACEUTICALS INC.
Patents 6,509,376; 7,320,999; 7,619,001; 7,803,840; 8,399,514; 8,759,393
Attorneys Aaron G. Clay; Adam S Ennis; Andrew E. Renison; Brandon M. White; Courtney M. Prochnow; David L. Anstaett; Emily J. Greb; Eric J. Fues; Frank X. Duff; Gordon H. Copland; James B. Monroe; James F. Companion; Jeanette M. Roorda; John E. Nappi; Laura P Masurovsky; Lauren J. Dowty; Li Feng; Michael A. Chajon; Paul W. Browning; Sandra K. Law; Sanya Sukduang; Shannon M Bloodworth; Travis L. Zeik; William J O'Brien
Firms Finnegan Henderson Farabow Garrett and Dunner; Perkins Coie LLC; Perkins Coie LLP; Perkins Coie LLP LA; Perkins Coie LLP Madison; Perkins Coie LLP Washington Dc; Perkins Coie, LLP; Schrader Companion Duff & Law, PLLC; Steptoe & Johnson PLLC - Bridgeport; Steptoe & Johnson PLLC, Cannonsburg
Link to Docket External link to docket
Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ‘376 patent”), 7,320,999 (“the…- 376 Patent, # 2 Exhibit B - 999 Patent, # 3 Exhibit C - 001 Patent, # 4 Exhibit D - 840 Patent, # 5 …“the ‘999 patent”), 7,619,001 (“the ‘001 patent”), 7,803,840 (“the ‘840 patent”), 8,759,393 (“the ‘393…393 patent”) and 8,399,514 (“the ‘514 patent”) arising under the patent laws of the United States, Title…5 Exhibit E - 393 Patent, # 6 Exhibit F - 514 Patent, # 7 Civil Cover Sheet)(lmm) (Entered: 06/30/2017 External link to document
0000-00-00 196 and affirmative defenses related to U.S. Patent Nos. 6,509,376; 7,320,999; 7,803,840; and 8,759,393. The…counterclaims and affirmative defenses as to U.S. Patent Nos. 7,619,001 and 8,399,514. Signed by Senior … 30 June 2017 1:17-cv-00116 835 Patent - Abbreviated New Drug Applications (ANDA) External link to document
0000-00-00 288 Order Parties to this patent infringement case involving U.S. Patent Nos. 8,399,514 (“the °514 patent”) and 7,619,001… 15-16 of the °514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the *001 patent under 35 U.S.C. § 271…and 15-16 of the 514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the °001 patent are not invalid and…7,619,001 (‘the 001 patent”); WHEREAS the Parties wish to narrow the issues in this litigation; WHEREAS…that it will not assert claims 17-19 of the 514 patent against Mylan (see ECF 102); THEREFORE, IT IS External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKesson
Mallinckrodt
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.